Palbociclib

IDEAYA Biosciences Appoints Catherine Mackey, Ph.D., to its Board of Directors

Retrieved on: 
Wednesday, April 6, 2022

SOUTH SAN FRANCISCO, Calif., April 6, 2022 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a synthetic lethality focused precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced the appointment of Catherine Mackey, Ph.D., to its Board of Directors. 

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., April 6, 2022 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a synthetic lethality focused precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced the appointment of Catherine Mackey, Ph.D., to its Board of Directors.
  • Dr. Mackey brings over 30 years of life sciences research, development and operational experience to IDEAYA.
  • Dr. Mackey also has considerable relevant experience as a Board Director of several public and private companies.
  • IDEAYA is applying its early research and drug discovery capabilities to synthetic lethality which represents an emerging class of precision medicine targets.

Investigation Report on China's Palbociclib Markets, 2021-2025: The World's First Selective Inhibitor of CDK 4/6 Launched by Pfizer - ResearchAndMarkets.com

Retrieved on: 
Monday, March 7, 2022

The "Investigation Report on China's Palbociclib Market 2021-2025" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Investigation Report on China's Palbociclib Market 2021-2025" report has been added to ResearchAndMarkets.com's offering.
  • Palbociclib is the world's first selective inhibitor of CDK 4/6 launched by Pfizer.
  • By inhibiting CDK 4/6, Palbociclib restores cell cycle control, thereby blocking tumor cell proliferation.
  • By 2020, Pfizer Europe MA EEIG is the only manufacturer in the Chinese Palbociclib market.

HR+/HER2- Breast Cancer Disease Market Analysis Research Report 2021 - ResearchAndMarkets.com

Retrieved on: 
Thursday, January 27, 2022

The "Disease Analysis: HR+/HER2- Breast Cancer" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Disease Analysis: HR+/HER2- Breast Cancer" report has been added to ResearchAndMarkets.com's offering.
  • Therefore, endocrine therapy remains the standard treatment for advanced patients with HR+/human epidermal growth factor receptor 2-negative (HER2-) breast cancer.
  • The publisher estimates that in 2018, there were 2.1 million incident cases and 8.6 million five-year prevalent cases of breast cancer worldwide.
  • By 2027, incident and prevalent cases of breast cancer are expected to increase to 2.3 million and 9.3 million cases, respectively.

Zanidatamab Data Presented at the San Antonio Breast Cancer Symposium (SABCS) Demonstrate Encouraging Antitumor Activity in Heavily Pretreated Patients with HER2-Positive Breast Cancer

Retrieved on: 
Wednesday, December 8, 2021

The data are being presented at the San Antonio Breast Cancer Symposium (SABCS) taking place in San Antonio, Texas and virtually, December 7-10, 2021.

Key Points: 
  • The data are being presented at the San Antonio Breast Cancer Symposium (SABCS) taking place in San Antonio, Texas and virtually, December 7-10, 2021.
  • The data presented at SABCS are from a clinical study of 24 patients with heavily pretreated HER2-positive metastatic breast cancer who received zanidatamab in combination with either vinorelbine (n=12), capecitabine (n=8), or paclitaxel (n=4).
  • As we await additional data in early lines of breast cancer, these data in late-line present an additional registrational opportunity.
  • We believe the data presented today demonstrate that zanidatamab and chemotherapy could be a new option for these patients.

Carrick Therapeutics Announces Collaboration with Roche to Evaluate Novel Samuraciclib Combination to Treat HR+ Breast Cancer

Retrieved on: 
Monday, August 2, 2021

The collaboration will utilize Roches MORPHEUS Phase 1b/2 platform for rapid and efficient combination development, with upfront randomization versus a control group.

Key Points: 
  • The collaboration will utilize Roches MORPHEUS Phase 1b/2 platform for rapid and efficient combination development, with upfront randomization versus a control group.
  • This new study expands Carricks portfolio of clinical trials with samuraciclib, which is also being evaluated in a Phase 2a study in combination with fulvestrant for CDK4/6i resistant HR+, HER2- metastatic breast cancer.
  • We are excited to initiate this collaboration with Roche to explore the broad potential of samuraciclib in combination with giredestrant, a next-generation oral SERD, said Tim Pearson, Chief Executive Officer of Carrick Therapeutics.
  • Samuraciclib is also being evaluated in triple negative breast cancer (TNBC) and prostate cancer with further potential in pancreatic, ovarian and colorectal cancers.

LianBio Appoints Pascal Qian as General Manager of China

Retrieved on: 
Monday, August 2, 2021

LianBio, a biotechnology company dedicated to bringing paradigm-shifting medicines to patients in China and other major Asian markets, today announced that it has appointed Pascal Qian to the position of China General Manager.

Key Points: 
  • LianBio, a biotechnology company dedicated to bringing paradigm-shifting medicines to patients in China and other major Asian markets, today announced that it has appointed Pascal Qian to the position of China General Manager.
  • Mr. Qian has extensive experience launching products in China, including Verzenio, Tyvyt, Elunate, Afinitor, Votrient, Sutent, Vfend and Singulair.
  • He has also led new product development initiatives in China for multiple globally developed drugs, including crizotinib, axitinib and palbociclib.
  • Mr. Qian most recently served as the Vice President, Head of Oncology Business Unit, at Lilly China.

TRIO Completes Enrolment for Phase 2 Giredestrant Early Breast Cancer Trial Ahead of Schedule

Retrieved on: 
Tuesday, July 6, 2021

The trial is investigating the ability to expand the safety and efficacy of giredestrant as monotherapy and in combination with palbociclib into the early breast cancer setting.

Key Points: 
  • The trial is investigating the ability to expand the safety and efficacy of giredestrant as monotherapy and in combination with palbociclib into the early breast cancer setting.
  • The trial design evaluates the efficacy, safety, and pharmacokinetics of presurgical treatment with giredestrant plus palbociclib compared with anastrozole plus palbociclib for postmenopausal women with ER+ and HER2-negative untreated early breast cancer.
  • The scale of interest from patients further underlines the urgency to bring forward new treatment options to treat early stage breast cancer.
  • TRIO advances translational cancer research by introducing innovative and novel targeted therapeutic concepts into the clinical trial setting.

G1 Therapeutics Presents Phase 1 Data at ASCO Describing Favorable Safety Profile and Evidence of Antitumor Activity of Rintodestrant Combined with Palbociclib in Patients with ER+/HER2- Advanced Breast Cancer

Retrieved on: 
Friday, June 4, 2021

The Phase 1, first-in-human, open-label study evaluated rintodestrant in women with ER+/HER2- advanced breast cancer after progression on endocrine therapy.

Key Points: 
  • The Phase 1, first-in-human, open-label study evaluated rintodestrant in women with ER+/HER2- advanced breast cancer after progression on endocrine therapy.
  • The study comprised three parts: dose escalation of monotherapy rintodestrant (part 1), dose expansion of monotherapy rintodestrant (part 2), and rintodestrant in combination with palbociclib therapy (part 3).
  • The results of part 1 and 2 were presented at the 2020 San Antonio Breast Cancer Symposium (SABCS) ( 2020 poster ).
  • G1 Therapeutics and the G1 Therapeutics logo are trademarks of G1 Therapeutics, Inc.

G1 Therapeutics Announces Upcoming Data at the American Society of Clinical Oncology (ASCO) Virtual 2021 Annual Meeting

Retrieved on: 
Wednesday, May 19, 2021

b'RESEARCH TRIANGLE PARK, N.C., May 19, 2021 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX ), a commercial-stage oncology company, today announced upcoming data presentations at the American Society of Clinical Oncology (ASCO) annual meeting, being held virtually June 4th through 8th.

Key Points: 
  • b'RESEARCH TRIANGLE PARK, N.C., May 19, 2021 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX ), a commercial-stage oncology company, today announced upcoming data presentations at the American Society of Clinical Oncology (ASCO) annual meeting, being held virtually June 4th through 8th.
  • The presentations will describe results from the Company\xe2\x80\x99s study of its oral selective estrogen receptor degrader (SERD), rintodestrant, in combination with palbociclib for the treatment of ER+/HER2- advanced breast cancer as well as data describing the effects of COSELA\xe2\x84\xa2 (trilaciclib) on T-cell activation and clonal expansion in patients with newly diagnosed extensive-stage small cell lung cancer.
  • G1 has a deep clinical pipeline and is executing a tumor-agnostic development plan evaluating COSELA in a variety of solid tumors, including colorectal, breast, lung, and bladder cancers.
  • G1 Therapeutics is based in Research Triangle Park, N.C. For additional information, please visit www.g1therapeutics.com and follow us on Twitter @G1Therapeutics .\nG1 Therapeutics\xe2\x84\xa2 and the G1 Therapeutics logo and COSELA\xe2\x84\xa2 and the COSELA logo are trademarks of G1 Therapeutics, Inc.\n'

Early amcenestrant data featured at ASCO support its potential to become a new endocrine backbone therapy for ER+/HER2- breast cancer

Retrieved on: 
Wednesday, May 19, 2021

\xe2\x80\x9cThe analysis also demonstrated no clinically significant cardiac or ocular findings and an overall safety profile in line with what we saw in the monotherapy setting.

Key Points: 
  • \xe2\x80\x9cThe analysis also demonstrated no clinically significant cardiac or ocular findings and an overall safety profile in line with what we saw in the monotherapy setting.
  • Amcenestrant 200mg daily in combination with palbociclib demonstrated a favorable overall safety profile (n=39), with treatment related adverse events (TRAEs) attributable to amcenestrant similar to those observed with monotherapy.
  • For all grade events, amcenestrant TRAEs occurred in 72% and to palbociclib in 90% of patients, and for grade \xe2\x89\xa53 in 15% and 46% of patients, respectively.
  • The most frequent non-hematological amcenestrant TRAEs included fatigue (18%) and nausea (18%), all grade \xe2\x89\xa42.